中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2011年
12期
916-920
,共5页
李迅%李妍%杨顺娥%马英%闻淑娟%郭莉%古力克孜%赵兵%刘炜%胡欣
李迅%李妍%楊順娥%馬英%聞淑娟%郭莉%古力剋孜%趙兵%劉煒%鬍訢
리신%리연%양순아%마영%문숙연%곽리%고력극자%조병%류위%호흔
乳腺肿瘤%新辅助化疗%生存素%乳腺癌耐药蛋白%人表皮生长因子受体2%基因表达%预后
乳腺腫瘤%新輔助化療%生存素%乳腺癌耐藥蛋白%人錶皮生長因子受體2%基因錶達%預後
유선종류%신보조화료%생존소%유선암내약단백%인표피생장인자수체2%기인표체%예후
Breast neoplasms%Neoadjuvant chemotherapy%Survivin%Breast cancer resistance protein%HER-2%Gene expression%Prognosis
目的 探讨生存素(Survivin)、乳腺癌耐药蛋白(BCRP)以及人表皮生长因子受体2(HER-2)基因表达对乳腺癌TE方案新辅助化疗疗效的预测价值.方法 对56例乳腺癌患者行TE方案新辅助化疗,应用RT-PCR法检测TE方案化疗前后Survivin、BCRP和HER-2 mRNA的表达差异,并结合化疗疗效进行相关性分析.结果 56例乳腺癌患者经TE方案新辅助化疗后的总有效率为71.4％.全组完全缓解5例,病理完全缓解4例,部分缓解35例,稳定13例,进展3例.Survivin mRNA的阳性表达率由化疗前的60.7％降至化疗后的35.7％ (P =0.008)；BCRP mRNA的阳性表达率由化疗前的37.5％降至化疗后的19.6％(P=0.036)；HER-2 mRNA的阳性表达率由化疗前的41.1％降至化疗后的21.4％ (P =0.025).Survivin或BCRP单独阴性表达的患者化疗的有效率均较阳性表达者高(均P＜0.05).HER-2 mRNA的单独表达状况与化疗疗效无关(P =0.144).Survivin、BCRP和HER-2 mRNA均为阴性表达的患者化疗疗效高于其他各组(P =0.003).在乳腺癌组织中,Survivin、BCRP和HER-2 mRNA的表达之间不存在相关关系(P＞0.05).结论 联合检测Survivin、BCRP和HER-2的表达可作为预测乳腺癌TE方案新辅助化疗敏感性的分子生物学指标.
目的 探討生存素(Survivin)、乳腺癌耐藥蛋白(BCRP)以及人錶皮生長因子受體2(HER-2)基因錶達對乳腺癌TE方案新輔助化療療效的預測價值.方法 對56例乳腺癌患者行TE方案新輔助化療,應用RT-PCR法檢測TE方案化療前後Survivin、BCRP和HER-2 mRNA的錶達差異,併結閤化療療效進行相關性分析.結果 56例乳腺癌患者經TE方案新輔助化療後的總有效率為71.4％.全組完全緩解5例,病理完全緩解4例,部分緩解35例,穩定13例,進展3例.Survivin mRNA的暘性錶達率由化療前的60.7％降至化療後的35.7％ (P =0.008)；BCRP mRNA的暘性錶達率由化療前的37.5％降至化療後的19.6％(P=0.036)；HER-2 mRNA的暘性錶達率由化療前的41.1％降至化療後的21.4％ (P =0.025).Survivin或BCRP單獨陰性錶達的患者化療的有效率均較暘性錶達者高(均P＜0.05).HER-2 mRNA的單獨錶達狀況與化療療效無關(P =0.144).Survivin、BCRP和HER-2 mRNA均為陰性錶達的患者化療療效高于其他各組(P =0.003).在乳腺癌組織中,Survivin、BCRP和HER-2 mRNA的錶達之間不存在相關關繫(P＞0.05).結論 聯閤檢測Survivin、BCRP和HER-2的錶達可作為預測乳腺癌TE方案新輔助化療敏感性的分子生物學指標.
목적 탐토생존소(Survivin)、유선암내약단백(BCRP)이급인표피생장인자수체2(HER-2)기인표체대유선암TE방안신보조화료료효적예측개치.방법 대56례유선암환자행TE방안신보조화료,응용RT-PCR법검측TE방안화료전후Survivin、BCRP화HER-2 mRNA적표체차이,병결합화료료효진행상관성분석.결과 56례유선암환자경TE방안신보조화료후적총유효솔위71.4％.전조완전완해5례,병리완전완해4례,부분완해35례,은정13례,진전3례.Survivin mRNA적양성표체솔유화료전적60.7％강지화료후적35.7％ (P =0.008)；BCRP mRNA적양성표체솔유화료전적37.5％강지화료후적19.6％(P=0.036)；HER-2 mRNA적양성표체솔유화료전적41.1％강지화료후적21.4％ (P =0.025).Survivin혹BCRP단독음성표체적환자화료적유효솔균교양성표체자고(균P＜0.05).HER-2 mRNA적단독표체상황여화료료효무관(P =0.144).Survivin、BCRP화HER-2 mRNA균위음성표체적환자화료료효고우기타각조(P =0.003).재유선암조직중,Survivin、BCRP화HER-2 mRNA적표체지간불존재상관관계(P＞0.05).결론 연합검측Survivin、BCRP화HER-2적표체가작위예측유선암TE방안신보조화료민감성적분자생물학지표.
Objective To study the changes of expression of Survivin mRNA,BCRP mRNA and HER-2 mRNA in breast cancer after TE regimen neoadjuvant chemotherapy,and to find biological markers to predict the efficiency of TE regimen neoadjuvant chemotherapy. Methods The gene expressions were detected by RT-PCR from 56 breast cancer patients before and after TE regimen neoadjuvant chemotherapy (docetaxel and epirubicin).The relationships between these gene expressions and chemotherapy responses were analyzed.Results The overall response rate to neoadjuvant chemotherapy was 71.4％,including 8.9％ (5/56) with complete response and 62.5％ (35/56) with partial response.Pathological complete response was found in 4 cases (7.1％ ).Stable disease and progression of disease were 23.2％ (13/56) and 5.4％ (3/56),respectively.The expression of Survivin mRNA after neoadjuvant chemotherapy was 35.7％ (20/56),significantly lower than 60.7％ (34/56) before neoadjuvant chemotherapy (P =0.008 ).The expression of BCRP mRNA after neoadjuvant chemotherapy was 19.6％,significantly lower than 37.5％before neoadjuvant chemotherapy (P =0.036).The positive rate of HER-2 mRNA expression was 41.1％ before the chemotherapy,and reduced to 21.4％ after the chemotherapy ( P =O.025 ).The effective rates of the single positive expression of Survivin mRNA or BCRP mRNA were both lower than that of negative expression ( P ＜0.05 ).The level of HER-2 mRNA expression alone was not significantly associated with the effective rate of chemotherapy (P =0.144).When the expression of all Survivin mRNA,BCRP mRNA and HER-2 mRNA were negative,the effective rate of neoadjuvant chemotherapy was higher than that in patients with positive expression ( P =0.003 ). The level of Survivin mRNA expression was not significantly associated with BCRP mRNA and HER-2 mRNA (P ＞ 0.05).Conclusion The expression of Survivin in combination with BCRP and HER-2 is associated with clinical response to TE neoadjuvant chemotherapy in breast cancer,and can be used as predictive biomarkers for chemosensitivity of TE regimen neoadjuvant chemotherapy for breast cancer.
